Thilo H. Pohle

Thilo H. Pohle

Auto-generated profile, based on publicly available information

Thilo H. Pohle

Department of Chemical and Biological Engineering University of Sheffield Sheffield UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2022 in Biotechnology Journal
Verified
Journal Article
Open access
YJYusuf B. Johari
Yusuf B. Johari
JSJoseph M. Scarrott
Joseph M. Scarrott
TPThilo H. Pohle
Thilo H. Pohle
PLPing Liu
Ping Liu
AMAyda Mayer
Ayda Mayer
DJDavid C. James
David C. James
Expression of recombinant genes in HEK293 cells is frequently utilized for production of recombinant proteins and viral vectors. These systems frequently employ the cytomegalovirus (CMV) promoter to drive recombinant gene transcription. However, the mechanistic basis of CMV‐mediated transcriptional activation in HEK293 cells is unknown and consequently there are no strategies to engineer CMV for controlled expression of recombinant genes. Extensive bioinformatic analyses of transcription factor regulatory elements (TFREs) within the human CMV sequence and transcription factor mRNAs within the HEK293 transcriptome revealed 80 possible regulatory interactions. Through in vitro functional testing using reporter constructs harboring discrete TFREs or CMV deletion variants we identified key TFRE components and clusters of TFREs (cis‐regulatory modules) within the CMV sequence. Our data reveal that CMV activity in HEK293 cells is a function of the promoters various constituent TFREs including AhR:ARNT, CREB, E4F, Sp1, ZBED1, JunB, c‐Rel, and NF‐κB. We also identified critical Sp1‐dependent upstream activator elements near the transcriptional start site that were required for efficient transcription and YY1 and RBP‐Jκ binding sites that mediate transrepression. Our study shows for the first time that novel, compact CMV‐derived promoters can be engineered that exhibit up to 50% higher transcriptional efficiency (activity per unit DNA sequence) or 14% increase in total activity compared to the wild‐type counterpart.

20 June 2024 in Biotechnology Journal
Verified
Journal Article
Open access
YJYusuf B. Johari
Yusuf B. Johari
TPThilo H. Pohle
Thilo H. Pohle
JWJared Whitehead
Jared Whitehead
JSJoseph M. Scarrott
Joseph M. Scarrott
PLPing Liu
Ping Liu
DJDavid C. James
David C. James
Recombinant adeno‐associated virus (rAAV) is the leading vector for the delivery of gene therapies. However, low viral genome (VG) titers are common and the proportion of “full” capsids containing the therapeutic gene payload can be highly variable. The coordinated molecular design of plasmids encoding viral components and Helper functions remains a major challenge for rAAV manufacturing. Here we present the design of improved Rep/Cap and Helper plasmids for rAAV2/8 production, (i) a Rep/Cap expression vector harboring independently controllable rep and cap genes and (ii) an improved Helper plasmid harboring E4 gene deletion variants. First, an optimized Rep/Cap vector utilized a truncated p5 promoter, a p5 cis‐regulatory element at the 3′ end in combination with a heterologous promoter to drive Cap expression and an additional copy of the rep52/40 gene to overexpress short Rep proteins. We demonstrate that Rep78 is essential for efficient rAAV2/8 production in HEK293 cells, and a higher ratio of short Rep to long Rep proteins enhances genome packaging. Second, we identified regulators and open reading frames within the Helper plasmid that contribute to increased rAAV2/8 production. While L4‐33k/22k is integral to optimal production, the use of E4orf6–6/7 subset significantly enhanced VG titer. Together, an optimal combination of engineered Rep/Cap and Helper plasmid variants increased VG titer by 3.1‐fold. This study demonstrates that configuring and controlling the expression of the different AAV genetic elements contributes toward high rAAV production and product quality (full/empty capsid ratio).